Loading...
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
BACKGROUND: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O(6)-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen an...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3551841/ https://ncbi.nlm.nih.gov/pubmed/23245659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-250 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|